Data Year:

For its 2026 fiscal year, IMMUNOVANT INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2026
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Peter Salzmann M.D.
Former Chief Executive Officer
Total Compensation $15,334,600 View details Pay Rank By Title In Biotechnology industry #55 View more
Eric Venker M.D., Pharm.D.
Chief Executive Officer, Director
Total Compensation $20,158,767 View details Pay Rank By Title In Biotechnology industry #29 View more
Eva Renee Barnett
Former Chief Financial Officer
Total Compensation $3,227,452 View details Pay Rank By Title In Biotechnology industry #134 View more
Jay S. Stout Ph.D.
Chief Technology Officer
Total Compensation $3,065,721 View details Pay Rank By Title In Biotechnology industry #7 View more
Melanie Gloria
Chief Operating Officer
Total Compensation $3,067,112 View details Pay Rank By Title In Biotechnology industry #59 View more
Michael Geffner M.D.
Former Chief Medical Officer
Total Compensation $5,254,089 View details Pay Rank By Title In Biotechnology industry #26 View more
Christopher Van Tuyl
Chief Legal Officer and Corporate Secretary
Total Compensation $2,295,777 View details Pay Rank By Title In Biotechnology industry #44 View more
Tiago Girao
Chief Financial Officer
Total Compensation $7,616,437 View details Pay Rank By Title In Biotechnology industry #21 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at IMMUNOVANT INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. IMMUNOVANT INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. IMMUNOVANT INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Peter Salzmann M.D.
Former Chief Executive Officer
Total Cash $39,614 Equity $14,557,344 Other $737,642 $15,334,600
Eric Venker M.D., Pharm.D.
Chief Executive Officer, Director
Total Cash $1,139,963 Equity $19,010,639 Other $8,165 $20,158,767
Eva Renee Barnett
Former Chief Financial Officer
Total Cash $26,250 Equity $2,813,771 Other $387,431 $3,227,452
Jay S. Stout Ph.D.
Chief Technology Officer
Total Cash $740,025 Equity $2,308,046 Other $17,650 $3,065,721
Melanie Gloria
Chief Operating Officer
Total Cash $740,025 Equity $2,308,046 Other $19,041 $3,067,112
Michael Geffner M.D.
Former Chief Medical Officer
Total Cash $345,521 Equity $4,709,989 Other $198,579 $5,254,089
Christopher Van Tuyl
Chief Legal Officer and Corporate Secretary
Total Cash $740,025 Equity $1,538,688 Other $17,064 $2,295,777
Tiago Girao
Chief Financial Officer
Total Cash $679,889 Equity $6,925,225 Other $11,323 $7,616,437
For its 2026 fiscal year, IMMUNOVANT INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Eric Venker M.D., Pharm.D. CEO Pay $20,224,962 Median Employee Pay $303,366 CEO Pay Ratio 67:1
For its 2025 fiscal year, IMMUNOVANT INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Andrew Fromkin Total Cash $530,036
Atul Pande, M.D. Total Cash $517,536
Douglas Hughes Total Cash $520,036
Eric Venker, M.D., Pharm.D. Total Cash $55,000
Frank M. Torti Total Cash $4,933,390
George Migausky Total Cash $522,536
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.